Public Profile

Crescendo Biologics Limited

Crescendo Biologics Limited, a pioneering biopharmaceutical company based in Great Britain, focuses on the development of innovative therapeutic solutions. Founded in 2008, Crescendo has established itself in the biotechnology industry, specialising in the creation of unique, fully human monoclonal antibodies and biologics. With a strong emphasis on its proprietary VH domain technology, the company aims to address unmet medical needs in oncology and autoimmune diseases. Crescendo's commitment to advancing biologics has positioned it as a notable player in the market, with significant achievements in drug development and strategic partnerships. As it continues to expand its operational reach, Crescendo Biologics remains dedicated to delivering cutting-edge therapies that enhance patient outcomes.

DitchCarbon Score

How does Crescendo Biologics Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

23

Industry Average

Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

4

Industry Benchmark

Crescendo Biologics Limited's score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.

23%

Let us know if this data was useful to you

Crescendo Biologics Limited's reported carbon emissions

Crescendo Biologics Limited, headquartered in Great Britain, currently does not have publicly available carbon emissions data or specific reduction targets. Without reported emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the company may be engaged in industry-standard practices aimed at sustainability and reducing environmental impact. As the landscape of corporate climate responsibility evolves, Crescendo Biologics Limited may consider establishing measurable targets and initiatives to align with global climate goals.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Crescendo Biologics Limited's primary industry is Research and development services (73), which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Crescendo Biologics Limited is in GB, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Crescendo Biologics Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Merus N.V.

NL
Health and social work services (85)
Updated about 13 hours ago

Regeneron

US
Pharmaceutical Preparation Manufacturing
Updated about 13 hours ago

Alloy Therapeutics, Inc.

US
Health and social work services (85)
Updated about 13 hours ago

Leveragen, Inc.

US
Health and social work services (85)
Updated about 13 hours ago

AbCellera

CA
Education services (80)
Updated about 13 hours ago

Ligand Pharmaceuticals Incorporated

US
Pharmaceutical Preparation Manufacturing
Updated about 13 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers